CY1110275T1 - Χημικη διαδικασια - Google Patents

Χημικη διαδικασια

Info

Publication number
CY1110275T1
CY1110275T1 CY20101100076T CY101100076T CY1110275T1 CY 1110275 T1 CY1110275 T1 CY 1110275T1 CY 20101100076 T CY20101100076 T CY 20101100076T CY 101100076 T CY101100076 T CY 101100076T CY 1110275 T1 CY1110275 T1 CY 1110275T1
Authority
CY
Cyprus
Prior art keywords
production
processes
relates
quinazoline derivatives
quinazoline
Prior art date
Application number
CY20101100076T
Other languages
English (en)
Inventor
Jörgen BLIXT
Michael David Golden
Philip John Hogan
David Michael Glanville Martin
Francis Joseph Montgomery
Zakariya Patel
John David Pittam
George Joseph Sependa
Christopher John Squire
Nicholas Cartwright Alexander Wright
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35395001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110275(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1110275T1 publication Critical patent/CY1110275T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Η παρούσα εφεύρεση αφορά χημικές διαδικασίες για την βιομηχανική παραγωγή ορισμένων παραγώγων κιναζολίνης, ή φαρμακευτικώς αποδεκτών αλάτων αυτών. Η εφεύρεση επίσης αφορά διαδικασίες για την βιομηχανική παραγωγή ορισμένων ενδιαμέσων χρήσιμων στην βιομηχανική παραγωγή των παραγώγων κιναζολίνης και διαδικασίες για την βιομηχανική παραγωγή των παραγώγων κιναζολίνης με την χρήση των εν λόγω ενδιαμέσων. Συγκεκριμένα, η παρούσα εφεύρεση αφορά χημικές διαδικασίες και ενδιάμεσα χρήσιμα στην βιομηχανική παραγωγή της ένωσης 4-(4-βρωμο-2-φθοροανιλινο)-6-μεθοξυ-7-(1-μεθυλπιπεριδιν-4-υλμεθοξυ)κιναζολίνης.
CY20101100076T 2005-09-30 2010-01-25 Χημικη διαδικασια CY1110275T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0519879.1A GB0519879D0 (en) 2005-09-30 2005-09-30 Chemical process
EP06794582A EP1943240B1 (en) 2005-09-30 2006-09-27 Chemical process

Publications (1)

Publication Number Publication Date
CY1110275T1 true CY1110275T1 (el) 2015-01-14

Family

ID=35395001

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20101100076T CY1110275T1 (el) 2005-09-30 2010-01-25 Χημικη διαδικασια
CY20101101019T CY1110887T1 (el) 2005-09-30 2010-11-12 Χημικη in situ διαδικασια σουλφουρωσης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20101101019T CY1110887T1 (el) 2005-09-30 2010-11-12 Χημικη in situ διαδικασια σουλφουρωσης

Country Status (32)

Country Link
US (8) US8163926B2 (el)
EP (2) EP1943240B1 (el)
JP (2) JP5213715B2 (el)
KR (1) KR101307641B1 (el)
CN (3) CN102503898B (el)
AR (1) AR055671A1 (el)
AT (2) ATE448218T1 (el)
AU (1) AU2006296367B2 (el)
BR (1) BRPI0616715A2 (el)
CA (2) CA2624045C (el)
CY (2) CY1110275T1 (el)
DE (2) DE602006010428D1 (el)
DK (2) DK1943240T3 (el)
ES (2) ES2350513T3 (el)
GB (1) GB0519879D0 (el)
HK (2) HK1122553A1 (el)
HR (2) HRP20100019T1 (el)
IL (2) IL190172A (el)
ME (2) ME01466B (el)
MY (2) MY149834A (el)
NO (1) NO342152B1 (el)
NZ (2) NZ593930A (el)
PL (2) PL1943240T3 (el)
PT (2) PT1943240E (el)
RS (2) RS51263B (el)
RU (1) RU2448102C2 (el)
SG (1) SG165416A1 (el)
SI (2) SI1943240T1 (el)
TW (2) TWI424991B (el)
UY (1) UY29824A1 (el)
WO (1) WO2007036713A2 (el)
ZA (1) ZA200802416B (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534171A (en) * 2002-02-01 2007-06-29 Astrazeneca Ab Quinazoline compounds for the treatment of diseases associated with angiogenesis and/or increased vascular permeability
GB0519879D0 (en) * 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
CL2007003158A1 (es) * 2006-11-02 2008-05-16 Astrazeneca Ab Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
EP2404595B1 (de) * 2011-09-01 2015-08-05 Symrise AG Verfahren zur Herstellung von Indanon-Derivaten
ES2678697T3 (es) * 2012-08-15 2018-08-16 Glaxo Group Limited Proceso químico
CN104098544A (zh) * 2013-04-07 2014-10-15 浙江九洲药物科技有限公司 一种凡德他尼的制备方法
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870083A (en) 1987-11-24 1989-09-26 Merrell Dow Pharmaceuticals Inc. 1,4-Disubstituted-piperidinyl compounds useful as analgesics and muscle relaxants
JP2829744B2 (ja) 1989-05-31 1998-12-02 川研ファインケミカル株式会社 ピペリジンカルボン酸類の製造方法
AU8506791A (en) 1990-10-01 1992-04-28 Janssen Pharmaceutica N.V. Novel 4-piperidinylcarbonyl derivatives
EP0646115B1 (en) 1991-03-28 2003-01-22 Eisai Co., Ltd. Heterocyclic-cyclic amine derivatives
DK0584222T3 (da) 1991-05-10 1998-02-23 Rhone Poulenc Rorer Int Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0638567A4 (en) 1993-02-18 1995-05-10 Kyowa Hakko Kogyo Kk ADENOSINE INHIBITORS.
HUT74870A (en) 1993-05-26 1997-02-28 Syntex Inc Process for producing 1-phenylalkanone 5-ht4 receptor ligands and pharmaceutical compositions containing them
DE4326344A1 (de) 1993-08-05 1995-02-09 Thomae Gmbh Dr K Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1995019344A1 (en) * 1994-01-13 1995-07-20 Merck Sharp & Dohme Limited Gem-disubstituted azacyclic tachykinin antagonists
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab, Soedertaelje 4-anilinochinazolin derivate
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EE05330B1 (et) 1999-11-05 2010-08-16 Astrazeneca Ab Kinasoliini derivaadid kui VEGF-i inhibiitorid
GB0126879D0 (en) 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
BR0215279A (pt) 2001-12-20 2005-05-10 Osi Pharmaceutical Inc Compostos antagonistas a2b seletivos da pirrolopirimidina, sua sìntese e uso
NZ534171A (en) 2002-02-01 2007-06-29 Astrazeneca Ab Quinazoline compounds for the treatment of diseases associated with angiogenesis and/or increased vascular permeability
EP1481971B1 (en) 2002-02-06 2011-11-16 Ube Industries, Ltd. Process for producing 4-aminoquinazoline compound
KR20050056190A (ko) 2002-08-09 2005-06-14 아스트라제네카 아베 암의 치료에서의 방사선 요법과 함께 혈관 내피 성장 인자수용체의 억제제인 ｚｄ6474의 병행 치료
GB0218526D0 (en) 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
AU2004212255B2 (en) 2003-02-13 2007-07-05 Astrazeneca Ab Combination therapy of ZD6474 with 5-FU or/and CPT-11
WO2005004870A1 (en) 2003-07-10 2005-01-20 Astrazeneca Ab Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
GB0318423D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
GB0519879D0 (en) * 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process

Also Published As

Publication number Publication date
NZ593930A (en) 2013-02-22
SI1943240T1 (sl) 2010-02-26
ES2350513T3 (es) 2011-01-24
EP2053048A1 (en) 2009-04-29
RS51263B (sr) 2010-12-31
GB0519879D0 (en) 2005-11-09
JP5654546B2 (ja) 2015-01-14
CN102503898A (zh) 2012-06-20
NO342152B1 (no) 2018-04-03
TWI424991B (zh) 2014-02-01
DE602006010428D1 (de) 2009-12-24
US20180118716A1 (en) 2018-05-03
MY145540A (en) 2012-02-29
KR20080049114A (ko) 2008-06-03
SG165416A1 (en) 2010-10-28
PT1943240E (pt) 2010-01-11
ZA200802416B (en) 2009-01-28
HK1130478A1 (en) 2009-12-31
EP1943240A2 (en) 2008-07-16
HRP20100620T1 (hr) 2010-12-31
HK1122553A1 (en) 2009-05-22
CA2624045C (en) 2012-05-22
CA2624045A1 (en) 2007-04-05
US20160185754A1 (en) 2016-06-30
US20090203905A1 (en) 2009-08-13
RU2008116573A (ru) 2009-11-10
IL227574A (en) 2015-08-31
US20140378684A1 (en) 2014-12-25
US20240150317A1 (en) 2024-05-09
CA2745829C (en) 2013-07-02
NZ566566A (en) 2011-08-26
WO2007036713A2 (en) 2007-04-05
ME01531B (me) 2014-04-20
US20120095229A1 (en) 2012-04-19
PL1943240T3 (pl) 2010-04-30
DE602006017004D1 (de) 2010-10-28
AR055671A1 (es) 2007-08-29
AU2006296367B2 (en) 2011-08-11
HRP20100019T1 (hr) 2010-02-28
CY1110887T1 (el) 2015-06-10
IL190172A0 (en) 2008-08-07
NO20081267L (no) 2008-04-30
US20190263782A1 (en) 2019-08-29
CN102503933B (zh) 2014-06-25
PT2053048E (pt) 2010-11-10
CN101277948A (zh) 2008-10-01
TWI328580B (en) 2010-08-11
RS51515B (en) 2011-06-30
SI2053048T1 (sl) 2010-12-31
BRPI0616715A2 (pt) 2011-06-28
US10344015B2 (en) 2019-07-09
ATE448218T1 (de) 2009-11-15
MY149834A (en) 2013-10-31
JP2009510039A (ja) 2009-03-12
TW201018660A (en) 2010-05-16
EP2053048B1 (en) 2010-09-15
WO2007036713A3 (en) 2007-06-14
JP2013063998A (ja) 2013-04-11
IL190172A (en) 2014-05-28
ME01466B (me) 2014-04-20
DK2053048T3 (da) 2010-11-29
ES2335435T3 (es) 2010-03-26
EP1943240B1 (en) 2009-11-11
CN101277948B (zh) 2013-03-13
EP2053048B8 (en) 2011-09-21
US20220033377A1 (en) 2022-02-03
PL2053048T3 (pl) 2011-03-31
CN102503933A (zh) 2012-06-20
RU2448102C2 (ru) 2012-04-20
TW200745036A (en) 2007-12-16
JP5213715B2 (ja) 2013-06-19
DK1943240T3 (da) 2010-03-01
KR101307641B1 (ko) 2013-09-12
UY29824A1 (es) 2007-04-30
CA2745829A1 (en) 2007-04-05
US9815816B2 (en) 2017-11-14
AU2006296367A1 (en) 2007-04-05
ATE481399T1 (de) 2010-10-15
US8163926B2 (en) 2012-04-24
US8865899B2 (en) 2014-10-21
CN102503898B (zh) 2015-03-25

Similar Documents

Publication Publication Date Title
CY1110275T1 (el) Χημικη διαδικασια
TW200833667A (en) Chemical process
CY1121043T1 (el) Θεραπευτικες ενωσεις
CY1117995T1 (el) Δευτεριωμενα παραγωγα κατεχολαμινης και φαρμακα που περιεχουν τις εν λογω ενωσεις
EA200700168A1 (ru) Производные замещенной циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы
TR201810944T4 (tr) Fgfr4 inhibitörleri olarak halka-füzyonlu bisiklik piridil türevleri.
CY1107419T1 (el) Προφαρμακα αντι-ιικων μεσων απο πιπεραζινη και υποκατεστημενη πιπεριδινη
CY1106598T1 (el) Παραγωγα κινολινης και ισοκινολινης, μεθοδος για την παραγωγη αυτων και χρηση αυτων ως αντιφλεγμονωδη μεσα
EA201000777A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
NO20084257L (no) Diketopiperazin og piperidin derivater som antivirale midler
EA201001769A1 (ru) Производные хинолинов и хиноксалинов в качестве ингибиторов протеинтирозинкиназы
CY1110835T1 (el) Διφαινυλ παραγωγα και η χρηση τους στη θεραπεια της ηπατιτιδας c
ATE551059T1 (de) Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
ECSP088358A (es) Tratamiento y profilaxis de microangiopatías
DE602008002934D1 (de) 2-cyclopropylthiazolderivate
EA200700982A1 (ru) Производные хинолина и изохинолина, замещённые в 5-ом положении, способ их получения и их применение в качестве противовоспалительных средств
CY1113314T1 (el) (3-αρυλ-πιπεραζιν-1-υλ) παραγωγα της 6,7-διαλκοξυκιναζολινης, 6,7-διαλκοξυφθαλαζινης και 6,7-διαλκοξυϊσοκινολινης
ATE477805T1 (de) 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität
CY1111954T1 (el) Παραγωγα τετραϋδροναφθαλινιου, μεθοδοι για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδη
CY1112718T1 (el) Ν- (2-υδροξυαιθυλ) -ν-μεθυλ-4- (κινολιν-8-υλ (1- (θειαζολ-4-υλμεθυλ) πιπεριδιν- 4 -υλιδενο) μεθυλ) βενζαμιδιο, η μεθοδος παρασκευης του καθως και η χρηση του για τη θεραπευτικη αγωγη πονου, αγχους και καταθλιψης
EA201001517A1 (ru) Замещенные пиперидины в качестве терапевтических соединений
MA33915B1 (fr) Nouveaux derives d' (heterocycle-piperidine condensee)-(piperazinyl)-1-alcanone ou d' (heterocycle-pyrrolidine condensee)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
UY29398A1 (es) Derivados de quinazolinas, sussales farmacéuticamente aceptables, composiciones que los contienen, procedimientos de preparación y aplicacións.
CY1120225T1 (el) Αλατα ενωσης βενζοθειαζολονης ως αγωνιστης του bhta-2-αδρενεργικου υποδοχεα
CL2008003551A1 (es) Uso de fosfato y fumarato de propionato de 3-(2,2,2-trimetilhidrazinio) en la preparacion de medicamentos utiles en la profilaxis y el tratamiento de aterosclerosis.